RAPT Therapeutics, Inc. (RAPT)
| Market Cap | 133.12M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -116.51M |
| Shares Out | 16.54M |
| EPS (ttm) | -10.97 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 19,411 |
| Open | 8.06 |
| Previous Close | 8.01 |
| Day's Range | 7.90 - 8.18 |
| 52-Week Range | 5.67 - 30.60 |
| Beta | -0.09 |
| Analysts | Buy |
| Price Target | 42.00 (+421.74%) |
| Earnings Date | Aug 7, 2025 |
About RAPT
RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company’s lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX47... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for RAPT stock is "Buy." The 12-month stock price target is $42.0, which is an increase of 421.74% from the latest price.
News
RAPT Therapeutics Names Two Industry Veterans to its Board of Directors
SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing an...
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discoverin...
RAPT Therapeutics to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing an...
RAPT Therapeutics Reports First Quarter 2025 Financial Results
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on d...
RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development
SOUTH SAN FRANCISCO, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing ...
RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
SOUTH SAN FRANCISCO, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”) is a clinical-stage immunology-based biopharmaceutical company focused ...
RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing a...
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing a...
RAPT Therapeutics Announces $150 Million Private Placement
SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and co...
Rapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient's Liver Injury
On Monday, Rapt Therapeutics, Inc. RAPT stock is trading lower after the company announced it was terminating its zelnecirnon (RPT193) program.
RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus
Data from phase 2b study, using zelnecirnon for the treatment of patients with atopic dermatitis, is expected in Q3 of 2024; Potential for FDA clinical hold to be removed. The global atopic dermatitis...
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Renovaro (NASDAQ:RENB)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity
RAPT Therapeutics' lead candidate, zelnecirnon, is in phase 2 for atopic dermatitis and asthma with very promising ph1b results in atopic dermatitis and potential expansion in multiple indications. Li...
RAPT Therapeutics Reports First Quarter 2024 Financial Results
SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and com...
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
- Confirmed objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status - Confirmed ORR of 17.4% in subset of patients with PD-L1+ disease - Confirmed ORR of 22.2% in subs...
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and c...
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
Includes late-breaking poster presentation to highlight phase 2 clinical data for tivumecirnon in head and neck cancer Includes late-breaking poster presentation to highlight phase 2 clinical data for...
RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK--(BUSINESS WIRE)---- $RAPT #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of RAPT Therapeutics, Inc. (“RAPT” ...
RAPT Therapeutics' stock plunges as FDA halts two clinical trials
RAPT Therapeutics Inc. shares RAPT, +1.68% dropped more than 60% premarket on Tuesday after the company said regulators have hit pause on two clinical trials of its experimental inflammation treatment...
FDA puts on hold two Rapt Therapeutics mid-stage drug trials
Rapt Therapeutics said on Tuesday the U.S. FDA had placed on hold two mid-stage trials of the company's drug to treat eczema and asthma, after liver failure was observed in one of the patients.
RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
- RAPT to host a conference call today at 8:30 am ET - SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biophar...
RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and co...
RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and co...
RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and co...